Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3465
Source ID: NCT05963022
Associated Drug: Tirzepatide
Title: A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes
Interventions: DRUG: Tirzepatide|DRUG: Placebo
Outcome Measures: Primary: Change from Baseline in Hemoglobin A1c (HbA1c), Baseline, Week 40 | Secondary: Percentage of Participants with HbA1c Target Values of <7.0% (<53 mmol/mol), Week 40|Change from Baseline in Fasting Serum Glucose, Baseline, Week 40|Percentage of Participants with HbA1c Target Values of ≤6.5% (≤48 mmol/mol), Week 40|Change from Baseline in Body Weight, Baseline, Week 40|Percentage of Participants with HbA1c Target Values of <5.7% (<39 mmol/mol), Week 40|Change from Baseline in Daily Average 7-Point Self-Monitored Blood Glucose Profiles (SMBG), Baseline, Week 40|Percentage of Participants Who Achieved Weight loss of ≥5%, Week 40|Percentage of Participants Who Achieved Weight loss of ≥10%, Week 40|Percentage of Participants Who Achieved Weight loss of ≥15%, Week 40
Sponsor/Collaborators: Sponsor: Eli Lilly and Company
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 168
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2023-08-21
Completion Date: 2024-10-09
Results First Posted:
Last Update Posted: 2024-10-21
Locations: Chinese PLA General Hospital, Beijing, Beijing, 100853, China|Shunde Hospital of Southern Medical Univesity, Foshan, Guangdong, 528399, China|Huizhou Municipal Central Hospital, Huizhou, Guangdong, 516001, China|Zunyi First People's Hospital, Zunyi, Guizhou, 563002, China|Hainan General Hospital, Haikou, Hainan, 570311, China|The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150001, China|The First Affiliated Hospital of Henan University of Science &Technology, Luoyang Shi, Henan, 471003, China|The First Affiliated Hospital of Nanyang Medical College, Nanyang, Henan, 473007, China|The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450014, China|Yichang Central People's Hospital, Yichang, Hubei, 443003, China|The First People's Hospital of Changde City, Changde, Hunan, 415003, China|The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210011, China|Nanjing First Hospital, Nanjing, Jiangsu, 210012, China|Nanjing Medical University - Nanjing Jiangning Hospital, Nanjing, Jiangsu, 211100, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215006, China|Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, 212000, China|Jiangxi Pingxiang People's Hospital, Pingxiang, Jiangxi, 337055, China|Dalian University - The Affiliated Zhongshan Hospital, Dalian, Liaoning, 116001, China|Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Dalian, Liaoning, 116033, China|Panjin Liaoyou Baoshihua Hospital, Liaoyou, Liaoning, 124009, China|The First Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi, 710077, China|Jinan Central Hospital, Jinan, Shandong, 250013, China|Pudong New Area People's Hospital Shanghai, Shanghai, Shanghai, 201200, China|Jiading District Central Hospital, Shanghai, Shanghai, 201800, China|West China Hospital of Sichuan University, Cheng Du, Sichuan, 610041, China|Chengdu Fifth People's Hospital, Chengdu, Sichuan, 611130, China|Tianjin Medical University General Hospital, Tianjin, Tianjin, 300052, China|Huzhou Central Hospital, Huzhou, Zhejiang, 313000, China
URL: https://clinicaltrials.gov/show/NCT05963022

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress